Powered by


The latest articles, press releases and dossiers on diagnostics in Baden-Württemberg

  • Article - 06-Oct-2014

    While there are specific regulations in Germany for the reimbursement of medicines, funding for molecular diagnostics products is complex and virtually non-existent. There is hardly any medical insurance cover for medical devices, which therefore tend to be sold on the open market. The question therefore arises as to how a reasonable price can be determined for innovative diagnostic methods and tools. In the second part of the interview conducted by Dr. Barbara Jonischkeit from BIOPRO Baden-Württemberg, Dr. Manfred Caeser, a pricing and reimbursement specialist at LSCN Ltd., explains the situation for us.

  • Article - 29-Sep-2014

    The company myPOLS Biotec UG, a spin-off from the University of Konstanz, specializes in services involving DNA and RNA polymerases and creates artificial enzymes by evolution in test tubes. These next-generation polymerases can be used for many research and diagnostics applications. myPOLS Biotec’s polymerases are promising enzymes for future applications with the potential to make the detection of pathogens and DNA analysis faster and easier.

  • Article - 08-Sep-2014

    After a traumatic experience, people often suffer not only mental, but also physical effects. Dr. María Moreno-Villanueva from the University of Konstanz has investigated the molecular effects of traumatic stress in people and has found a higher than normal number of DNA strand breaks. In the worst cases this can lead to diseases such as cancer. However, her study also shows that successful psychotherapy can reverse DNA damage. Her findings will contribute to the development of new methods for the diagnosis and therapy of traumatic stress disorders.

  • Article - 11-Aug-2014

    PCR has become a common application in medical diagnostics, in areas ranging from the detection of microbes to genetic testing. The demand for new tests is huge, given that there is a seemingly endless list of applications for which PCR can be used. dsl-Labor für Molekulargenetische Diagnostik specialises in the development of PCR tests and also gives advice and training to medical laboratory personnel. Veterinarians are among the company’s major clients since the rapid and reliable diagnosis of disease plays a particularly important role in animal husbandry.

  • Article - 30-Jun-2014

    A large-scale long-term cohort study will be carried out to explain the causes of widespread diseases, in particular cancer, coronary heart disease, stroke and diabetes, and to identify the risk factors that lead to or favour the development of a certain disease. The principal objective of the German National Cohort (GNC) is to create the conditions that enable the development of new strategies for the prevention, risk assessment and early detection of chronic diseases.

  • Article - 30-Jun-2014

    Epigenetic DNA modifications have been shown to play a role in carcinogenesis and are therefore a promising target for the early detection of cancer. Dr. Daniel Summerer and his research group at the University of Konstanz have developed a method that enables the direct and site-specific identification of epigenetic changes. The method represents a new approach in the field of epigenetic analysis as well as a major step towards simpler cancer diagnosis.

  • Dossier - 02-Jun-2014

    Science constantly provides researchers with new challenges biologists and bioanalysts have to deal with and which come from sources as varied as the ever increasing number of resistant pathogenic bacterial strains or the famine conditions in Third-World countries. In the search for scientific truths bioanalysis is the development optimization and application of the entire range of analytical methods available. However we need to keep in mind that although this leads to an expansion of knowledge the truth is only temporary.

  • Article - 02-Jun-2014

    Spectroscopic methods have been used for many decades in scientific research to obtain a wealth of information about chemical substances, substance mixtures and their reaction processes. Micro-biolytics GmbH from Esslingen have successfully developed a spectroscopic method that combines innovative technologies. The method enables the highly accurate and sensitive measurement of aqueous samples.

  • Press release - 27-May-2014

    Comprehensive genome analyses of cancer cells have shown that each tumor and cancer patient are unique and need to be treated individually. To pave the way, by 2015 the National Center for Tumor Diseases (NCT) Heidelberg aims to offer cancer patients at the NCT analyses of their individual cancer genomes to be used as the basis for personalized recommendations for treatment. This initiative from the DKFZ and NCT has been made possible by generous support from the Dietmar Hopp Foundation. The long-term goal is to facilitate the transition of research findings into applications and thus make individualized cancer treatment a part of standard clinical care. Leading technology companies including SAP, Molecular Health and GATC Biotech are collaborating in the project.

  • Article - 28-Apr-2014

    Sciomics GmbH is a start-up biotech from Heidelberg with a special focus on protein microarrays. Sciomics produces complex, high-density antibody microarrays for cancer-relevant proteins and offers services for medical research, diagnostics and the industry, including biomarker screening, the verification of biomarker candidates, the analysis and localization of drug targets and their signalling pathways as well as the characterization of antibodies. In addition, Sciomics produces and markets microarrays that are adapted to the specific research issues of its customers.

  • Article - 07-Apr-2014

    BIPSO GmbH, based in Singen, Germany, has been manufacturing contrast agents for applications in modern medical diagnostics since 2011. BIPSO is part of the Bracco Imaging Group, which is one of the world’s leading specialists in the diagnostic imaging business, and produces imaging agents mainly for Bracco’s sales organisations. The company has recently invested in the expansion of its manufacturing site in Singen with the goal of consolidating its leading position both now and in the future.

  • Article - 31-Mar-2014

    TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug effects and costs.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/diagnostics/?block_75783size=12&block_75783from=72